- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07445763
Исследование реальной клинической практики TARSILA (TARSILA)
Эффективность вакцинации матери препаратом RSVpreF против острой респираторной инфекции, ассоциированной с РСВ, у младенцев в Бразилии в реальных условиях (исследование TARSILA): многоцентровое, проспективное, тест-негативное, исследование случай-контроль
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Maicon Falavigna, MD PhD
- Номер телефона: +55 51 2399 1750
- Электронная почта: research@inovamedical.com.br
Места учебы
-
-
Paraná
-
Cascavel, Paraná, Бразилия, 85818-130
- Рекрутинг
- Unidade de Pronto Atendimento Veneza
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Curitiba, Paraná, Бразилия, 80060-900
- Рекрутинг
- Complexo do Hospital de Clínicas da Universidade Federal do Paraná
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Главный следователь:
- Cristina de Oliveira Rodrigues
-
Curitiba, Paraná, Бразилия, 80240-031
- Рекрутинг
- Hospital Infantil Pequeno Príncipe
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Главный следователь:
- Heloisa Ihle Garcia Giamberardino
-
Marechal Cândido Rondon, Paraná, Бразилия, 85960-000
- Рекрутинг
- Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Palotina, Paraná, Бразилия, 85950-000
- Рекрутинг
- Unidade de Saúde Central de Palotina
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Toledo, Paraná, Бразилия, 85902-480
- Рекрутинг
- Unidade de Pronto Atendimento II de Toledo
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 91350-200
- Рекрутинг
- Hospital Nossa Senhora da Conceição
-
Контакт:
- Maicon Falavigna, PhD
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Главный следователь:
- Fernanda H Varela
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90035-903
- Рекрутинг
- Hospital de Clínicas de Porto Alegre
-
Контакт:
- Maicon Falavigna
- Номер телефона: +555123991750
- Электронная почта: research@inovamedical.com.br
-
Главный следователь:
- Ricardo Becker Feijó
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Infants with acute respiratory illness (ARI)
Описание
Tarsila Inpatient Study
Inclusion Criteria
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Maternal or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Infant previously enrolled in this study.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
Tarsila Outpatient Study
Inclusion Criteria:
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Mother or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
- Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: CASE_CONTROL
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Cases
Infants with a positive respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
|
Controls
Infants with a negative respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing). |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Временное ограничение: Occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring). |
Occurring ≤180 days after birth.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) . |
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Временное ограничение: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness. |
ARI occurring ≤180 days after birth
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization. |
Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
|
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) . |
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
RT-qPCR-confirmed RSV-positive LRTD in-hospital death. |
Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
|
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization. |
Hospitalization occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Временное ограничение: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed HMPV-positive LRTD hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Временное ограничение: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by:
|
ARI occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Временное ограничение: ARI occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness. |
ARI occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Временное ограничение: LRTD occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤180 days after birth.
|
|
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Временное ограничение: LRTD occurring ≤360 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤360 days after birth.
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Maicon Falavigna, Inova Medical
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
- CAAE 95166426.7.1001.0008
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .